NRAS and melanoma: Obviously, it is a proof of concept that interfering with mitochondrial dynamics and bioenergetics sensitizes NRAS mutant melanoma cells to vemurafenib, since these inhibitors and uncouplers have systemic toxicity and can compromise the energy homeostasis of other tissues, such as the heart and brain, making their therapeutic use unfeasible [78].